- Trials with a EudraCT protocol (1,303)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (15)
1,303 result(s) found for: Bacterial Infections..
Displaying page 34 of 66.
| EudraCT Number: 2023-000005-12 | Sponsor Protocol Number: CRCFC-TEICO.SA.2022 | Start Date*: 2024-02-21 | ||||||||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | ||||||||||||||||||
| Full Title: An open-label study to evaluate the safety and tolerability of inhaled Teicoplanin in the treatment of Staphylococcus aureus (including mrsa) infections in CYSTIC FIBROSIS PATIENTS | ||||||||||||||||||
| Medical condition: cystic fibrosis associated to persistent Staphylococcus aureus (including MRSA) infection | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2018-001582-16 | Sponsor Protocol Number: RF-2016-02361583 | Start Date*: 2018-08-09 | |||||||||||
| Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO | |||||||||||||
| Full Title: Efficacy of Albumin Replacement and Balanced Crystalloid Solutions in Septic Shock (the ALBIOSS-BALANCED trial): a 2-by-2 factorial, investigator-initiated, open-label, multicenter, randomized, con... | |||||||||||||
| Medical condition: Septic shock | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-002727-15 | Sponsor Protocol Number: 114174 | Start Date*: 2015-06-22 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A phase II, randomized, controlled, observer-blind study to evaluate the impact of two formulations of GlaxoSmithKline (GSK) Biologicals’ combined 10-valent pneumococcal polysaccharide and non-type... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Healthy volunteers (for one-dose vaccination of healthy children between 2-4 years of age at the time of vaccination against Streptococcus pneumoniae (S. pneumoniae) and Haemophilus influenzae (H. ... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2016-005161-31 | Sponsor Protocol Number: AT-201 | Start Date*: 2017-07-04 | ||||||||||||||||
| Sponsor Name:Allecra Therapeutics SAS | ||||||||||||||||||
| Full Title: Randomized, Double-Blind, Multi-Center Study of Cefepime/AAI101 in Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis | ||||||||||||||||||
| Medical condition: Complicated urinary tract infections including acute pyelonephritis | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: HU (Completed) PL (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2018-003379-37 | Sponsor Protocol Number: VLA15-201 | Start Date*: 2019-05-20 | |||||||||||||||||||||
| Sponsor Name:Valneva Austria GmbH | |||||||||||||||||||||||
| Full Title: IMMUNOGENICITY AND SAFETY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER... | |||||||||||||||||||||||
| Medical condition: Prevention against Lyme borreliosis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DE (Completed) BE (Completed) AT (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2020-000508-13 | Sponsor Protocol Number: 72779 | Start Date*: 2020-10-27 | |||||||||||
| Sponsor Name:Princess Máxima Center for Pediatric Oncology | |||||||||||||
| Full Title: An open-label, randomized clinical trial on teicoplanin infection prophylaxis in pediatric patients with acute myeloid leukemia | |||||||||||||
| Medical condition: Acute myeloid leukemia | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-003487-36 | Sponsor Protocol Number: 1 | Start Date*: 2015-12-23 | |||||||||||
| Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust | |||||||||||||
| Full Title: Alternatives to prophylactic antibiotics for the treatment of recurrent urinary tract infection in women | |||||||||||||
| Medical condition: Recurrent urinary tract infection in women | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-003405-42 | Sponsor Protocol Number: 201532 | Start Date*: 2018-01-16 | |||||||||||
| Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
| Full Title: A phase III, open-label, single-group, multi-centre study to assess the immunogenicity, safety and reactogenicity of GSK Biologicals’ combined reduced antigen content diphtheria, tetanus and acellu... | |||||||||||||
| Medical condition: Healthy volunteers [Booster immunisation against diphtheria, tetanus and pertussis diseases of individuals from age of four years onwards. The study population for this study will include individua... | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-021018-49 | Sponsor Protocol Number: FOILED | Start Date*: 2012-05-25 | ||||||||||||||||
| Sponsor Name:GWT-TUD GmbH | ||||||||||||||||||
| Full Title: Fish OIL optimal dosE Determination Study | ||||||||||||||||||
| Medical condition: Mechanically ventilated adult patients (>18 years old) admitted to ICU with clinical evidence of sepsis, sepsis associated organ dysfunction, and high expression of inflammatory cytokines. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2009-012087-13 | Sponsor Protocol Number: B1851022(6115A1-3003-WW) | Start Date*: 2009-12-04 | |||||||||||
| Sponsor Name:Wyeth Pharmaceuticals Inc., acting through its division Wyeth Research, a Pfizer Company | |||||||||||||
| Full Title: A Phase 3, Open-label Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine in Recipie... | |||||||||||||
| Medical condition: Pneumococcal infection | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) DE (Completed) SE (Completed) FR (Completed) NL (Completed) ES (Completed) CZ (Completed) Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-002207-26 | Sponsor Protocol Number: TP-434-021 | Start Date*: 2016-12-15 | |||||||||||
| Sponsor Name:Tetraphase Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared with Ertapenem in Complicated Urinary Tract Infections | |||||||||||||
| Medical condition: Complicated Urinary Tract Infections | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: LV (Completed) AT (Completed) SK (Completed) PL (Completed) BG (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-003244-13 | Sponsor Protocol Number: D4280C00016 | Start Date*: 2015-04-17 | |||||||||||
| Sponsor Name:Pfizer Inc. | |||||||||||||
| Full Title: A single blind, randomised, multi-centre, active controlled, trial to evaluate safety, tolerability, pharmacokinetics and efficacy of ceftazidime and avibactam compared with cefepime in children fr... | |||||||||||||
| Medical condition: Complicated urinary tract infections | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) CZ (Completed) GR (Completed) PL (Completed) RO (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-005104-33 | Sponsor Protocol Number: ALS-8176-503 | Start Date*: 2014-02-14 | |||||||||||
| Sponsor Name:Janssen Research & Development, LLC | |||||||||||||
| Full Title: A Randomized, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered ALS-008176 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dosing... | |||||||||||||
| Medical condition: Respiratory Syncytial Virus (RSV) Infection | |||||||||||||
|
|||||||||||||
| Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) FR (Completed) RO (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-000801-39 | Sponsor Protocol Number: PsAer-IgY | Start Date*: 2011-08-31 | |||||||||||
| Sponsor Name:Mukoviszidose Institute gGmbH | |||||||||||||
| Full Title: Prospective randomized, placebo-controlled, double blind, multicenter study (phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention ... | |||||||||||||
| Medical condition: Cystic fibrosis (CF) is a chronic and progressive genetic disease of the body's exocrine glands. CF especially affects the respiratory system. A common effect leads to massive production of abnorma... | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) SE (Completed) BE (Completed) IT (Completed) IE (Completed) HU (Completed) AT (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-003242-28 | Sponsor Protocol Number: D4280C00015 | Start Date*: 2015-05-20 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A single blind, randomised, multi-centre, active controlled, trial to evaluate safety, tolerability, pharmacokinetics and efficacy of ceftazidime and avibactam when given in combination with metron... | |||||||||||||
| Medical condition: Complicated Intra-Abdominal Infection (cIAI) | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) ES (Completed) CZ (Completed) GR (Completed) RO (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-004556-38 | Sponsor Protocol Number: TP-434-010 | Start Date*: 2014-02-24 | |||||||||||
| Sponsor Name:Tetraphase Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Levofloxacin in Complicated Urinary Tract Infections | |||||||||||||
| Medical condition: Complicated urinary tract Infections | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) DE (Completed) IT (Completed) EE (Completed) CZ (Completed) LV (Completed) GR (Completed) BG (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-001699-43 | Sponsor Protocol Number: BPR-CS-009 | Start Date*: 2018-12-13 | |||||||||||
| Sponsor Name:Basilea Pharmaceutica International Ltd | |||||||||||||
| Full Title: A randomized, double-blind, multi-center study to establish the efficacy and safety of ceftobiprole medocaril compared to daptomycin in the treatment of Staphylococcus aureus bacteremia, including ... | |||||||||||||
| Medical condition: Complicated staphylococcus aureus bacteremia (cSAB) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) HU (Completed) BG (Completed) ES (Completed) IT (Completed) GR (Completed) PT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-001585-15 | Sponsor Protocol Number: 2018-01671 | Start Date*: 2020-01-30 |
| Sponsor Name:Centre Hospitalier Universitaire Vaudois | ||
| Full Title: PTX3 genetically stratified randomized double-blinded allocation eventdriven clinical trial for antifungal prophylaxis in patients with acute myeloid leukemia | ||
| Medical condition: Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome in transformation (MDSit) who receive antifungal profylaxis during their treatment with an intensive chemotherapy regimen, inc... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2025-000103-23 | Sponsor Protocol Number: MEQ00075 | Start Date*: 2025-04-09 | |||||||||||
| Sponsor Name:Sanofi Pasteur Inc. | |||||||||||||
| Full Title: Phase I Open-Label, Age De-escalation Safety and Immunogenicity Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents, Children, Toddlers, and Infants in C... | |||||||||||||
| Medical condition: Meningococcal infection | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-003040-39 | Sponsor Protocol Number: CTBM100G2202 | Start Date*: 2016-09-29 | ||||||||||||||||
| Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
| Full Title: A randomized, blinded, parallel group, multi-center dose-finding study, to assess the efficacy, safety and tolerability of different doses of tobramycin inhalation powder in patients with Non-Cysti... | ||||||||||||||||||
| Medical condition: Pseudomonas aeruginosa infection in patients with non-cystic fibrosis bronchiectasis | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Prematurely Ended) BE (Completed) DE (Completed) IE (Completed) NL (Completed) GB (Completed) FR (Completed) IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.